Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous adipose decellularized active protein (ADAP) is a bioactive regenerative material derived from a patient's own adipose tissue. The production process involves the decellularization of lipoaspirate to remove cellular components and lipid droplets while preserving the natural extracellular matrix (ECM) structure and a concentrated pool of endogenous growth factors, including VEGF, bFGF, and TGF-β. ADAP acts as both a biological scaffold and a reservoir of signaling molecules that promote angiogenesis, fibroblast proliferation, and collagen synthesis. It is primarily investigated in plastic and reconstructive surgery for facial rejuvenation, the treatment of atrophic scars, and soft tissue augmentation, offering a biocompatible alternative to synthetic fillers or traditional fat grafting with potentially higher retention rates and regenerative capacity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous adipose decellularized active protein.